Geert’s Concern about the New Covid Variant (JN.1)

Geert’s extensive background in virology and vaccine development. • 1:32

His concerns about mass vaccination during a pandemic. • 3:00

Examples of past vaccination campaigns leading to detrimental consequences. • 7:01

Criticism of global health organizations for silencing critical voices. • 8:33

Geert criticizes the vaccine industry’s focus on profit over public health. • 10:04

He emphasizes the importance of preventing infection in a global health context to fight a pandemic. • 13:23

Geert warns about the self-perpetuating cycle of immune escape variant generation due to mass vaccination. • 14:34

He highlights the short-sightedness of politicians and public health authorities in addressing the disastrous consequences for the healthcare system. • 15:42

Highly vaccinated populations are unable to stop the virus from circulating, leading to a continuous cycle of variants. • 16:32

The virus continues to evolve, preventing the development of herd immunity and leading to breakthrough infections. • 17:03

The current approach to control the virus has not been effective, and the situation is not sustainable. • 18:17

The vaccine’s inability to control the virus and its impact on immune responses raise questions about its classification as a traditional vaccine. • 20:07

The vaccine induces immune refocusing, leading to a chain of irreversible consequences. • 24:09

Vaccine-induced antibodies refocus immune response to less immunogenic epitopes. • 24:29

Vaccine breakthrough infections boost previously induced antibodies to high titer. • 26:05

Boosted antibodies recognize subdominant epitopes, inducing cross neutralizing antibodies. • 27:50

Cross neutralizing antibodies exert suboptimal immune pressure, promoting more infectious variants. • 29:39

mRNA vaccines induce low affinity antibodies targeting less immunogenic epitopes. • 30:38

Manufacturers overlooked the generation of low affinity antibodies in mRNA vaccines. • 32:15

Only a small proportion of antibodies target the new variant ba286. • 32:48

The primary immune response is not improving, indicating a serious situation. • 32:57

Administering vaccines or booster doses may accelerate immune escape. • 33:58

Low affinity antibodies only interact with multimeric virus presentation, leading to pseudo neutralization. • 34:52

Antibodies with diminished neutralizing capacity can enhance infection by masking immunogenic epitopes. • 39:04

Recognition of previously non-immunogenic epitopes can lead to the production of non-neutralizing antibodies. • 40:20

The conserved antigenic site within the Spike protein can be targeted by the immune system, leading to enhanced infection. • 40:46

Low affinity antibodies stabilize viral aggregates, promoting immune evasion. • 41:08

Evolution of gn1 variant indicates significant immune pressure and ongoing viral evolution. • 46:07

Ba2.86 mutations show continuous evolution of the virus. • 48:07

The new variant, gn1, is spreading rapidly and outpacing other variants globally. • 52:01

There is a surge in hospitalization, severe disease, and death related to the new variant. • 52:23

Mutations in gn1 are not limited to conserved domains and are uncommon, rare, and not spike-specific. • 52:53

These mutations have an infection-enhancing effect, promoting viral protein synthesis and intracellular replication. • 53:50

The immune pressure on the virus has moved away from targeting common epitopes and even epitopes within Spike. • 54:53

The observation suggests that the infection mitigation is now driven by cytotoxic T cells (CTLs). • 56:03

There is a shift towards CTLs targeting a universal epitope shared among coronaviruses, not specific to Spike. • 56:28

The theory indicates a potential stage where CTLs take over in mitigating the infection. • 57:18

CTLS cannot prevent infection due to lack of memory. • 57:49

New variant mutations target universal epitopes, affecting immune response. • 58:41

Shift from antibody to cell-mediated immune response observed. • 59:37

Antigen presenting cells overwhelmed by larger aggregates, impacting vaccine efficacy. • 1:01:02

Diminishing concentration of infection-enhancing antibodies poses a disaster. • 1:05:10

Antibodies with weak affinity can block trans infection, affecting virus transfer to susceptible cells in organs. • 1:05:43

CTL-mediated mitigation of infection can diminish concentration of infection-enhancing antibodies. • 1:06:14

Immunological pressure on virus virulence may lead to fitness cost and reduced infectiousness. • 1:06:43

Unvaccinated individuals rely on trained innate immune system, while vaccinated individuals may have a corrupted adaptive immune system. • 1:08:19

Viral circulation poses a risk of recurring infection for both vaccinated and unvaccinated individuals. • 1:11:44

Epigenetic changes impact the functionality of innate immune cells, similar to physical training. • 1:12:43

Observation of the Covid crisis as a fight between stakeholders and underdogs. • 1:13:16

Importance of innate immunity in dealing with variants. • 1:14:06

Focus on debates and lawsuits rather than virus evolution. • 1:15:11

Prediction of tremendous losses due to the new variant. • 1:20:09

Warning about the emergence of a highly infectious new variant. • 1:20:15

Shift in reliance from antibodies to CTLS for infection mitigation. • 1:21:22

Criticism of public health authorities’ messaging and strategies. • 1:24:19

Prediction of rapid evolution and impact of the new variant. • 1:24:31

Emphasis on the urgency of the situation and need for immediate action. • 1:24:41

Assertion that the current situation renders previous discussions obsolete. • 1:24:50

Call for scientists to verify neutralizing antibody effectiveness. • 1:25:35

Concerns about the potential virulence in highly vaccinated populations. • 1:27:14

Prediction of exponential increase in mortality and morbidity rates. • 1:27:32

Vaccinated individuals at risk of increased mortality and morbidity. • 1:27:40

Urgent recommendation for thorough vaccination and antivirus usage. • 1:28:15

Prediction of exponential growth in virus spread. • 1:28:25

Anticipation of mandates for antivirus usage. • 1:28:40

Acknowledgment of monumental crisis and potential window of opportunity for suppression. • 1:29:31

Importance of taking action to mitigate the disaster. • 1:30:08

Expression of disbelief at the scale of the disaster. • 1:30:45

Emphasis on thorough research and conviction in the presented analysis. • 1:31:20

Comparison of situation to predicting a volcano eruption based on surface vs. underground analysis. • 1:33:26

Geert speaks from the heart and has genuine conviction. • 1:34:42

He is willing to make his voice heard despite potential criticism. • 1:34:51

Acknowledgement of the difficult message being shared. • 1:35:33